1 active not recruiting, 1 completed, 1 recruiting, 1 withdrawn. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Giapreza: new trials by email Literature Review of Giapreza trials Research Report on Giapreza
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT) Angiotensin II (Giapreza®), Yttrium-90 radioembolization - Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult | Phase 2 | Recruiting | Niek Wijnen | 15 | 2026-01-01 | 2026-03-30 |
| Angiotensin II in Liver Transplantation Angiotensin II, Saline - Liver Transplant; Complications, Vasoplegia | Phase 2 / Phase 3 | Active not recruiting | University of California, San Francisco | 50 | 2022-06-28 | 2026-03-20 |
| Angiotensin 2 for Hepatorenal Syndrome Angiotensin II, Midodrine, Octreotide - Hepatorenal Syndrome, Cirrhosis | Phase 2 | Withdrawn | University of California, Los Angeles | 2021-07-01 | 2024-03-06 | |
| A Study of LJPC-501 in Pediatric Patients With Hypotension Angiotensin II - Catecholamine-resistant Hypotension (CRH), Distributive Shock | Phase 2 | Completed | La Jolla Pharmaceutical Company | 2 | 2018-02-11 | 2018-08-07 |
Acute Kidney Injury (2) · Fibrosis (2) · Carcinoma, Hepatocellular (1) · Hepatorenal Syndrome (1) · Hypotension (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Sepsis (1) · Vasoplegia (1)
La Jolla Pharmaceutical Company (1) · Niek Wijnen (1) · University of California, Los Angeles (1) · University of California, San Francisco (1)
United States (2) · Netherlands (1)
Michael P Bokoch, M.D., Ph.D. (1)
2025 (1)